bind the soluble TNF. To date, very few data are available concerning the use of biosimilar drugs in a real-life setting. Results from DANBIO registry suggested a lower retention rate in RA patients switchers from Enbrel® to biosimilar etanercept (ETN) in comparison with the historic ETN patients (1).**

**Objectives:** To compare the efficacy of ETA versus SB4 in a cohort of RA patients in a real-life setting.

**Methods:** In this monocentric case-control prospective study, we consecutively enrolled RA patients starting ETA or SB4 treatment from 2015. RA diagnosis was made according to ACR/EULAR 2010 criteria (2). Data were collected and entered into a standardized, computerized, electronically filled-in form. We included patient demographics, date of diagnosis, comorbidities and previous and concomitant medications. The clinical evaluation included the count of swollen and tender joints and the patient’s and physician’s global disease assessment based on a visual analogue scale (VAS; range, 0 to 100 mm). Disease activity was measured according to the disease activity score in 28 joints (DAS28ESR) (3). The patients were asked to fill in the Health Assessment Questionnaire (HAQ). All the patients were evaluated at the beginning of treatment (T0) and after 4 (T1) and 12 months (T2). Clinical response to treatment was evaluated by using EULAR criteria (4).

**Results:** We evaluated 35 RA patients treated with SB4 (M/F 2/33; median age 63 years, IQR 21; median disease duration 108 months, IQR 138) and 40 with ETA (M/F 5/35; median age 60.5 years, IQR 20; median disease duration 102 months, IQR 141). Biologic drug was prescribed as first-line biological treatment in 71.4% of SB4 cohort and in 80.0% of ETA. At T0 no significant differences were observed among the two groups in terms of DAS28ESR [SB4 median 4.6 (IQR 1.8), ETA 4.3 (IQR 1.9), p=ns] and HAQ [SB4: median 1 (IQR 1.05), ETA median 1 (IQR 0.85), p=ns]. In both groups we observed a significant reduction of DAS28ESR values after 4 and 12 months of treatment, similarly to ETA. Nonetheless, ETA seems to be able to induce a remission status earlier than SB4. For ETA, no correlation was found with both of residual DC and DC+ was significantly correlated with the presence of FcgRIIA 131-R. In fact, none of the HH-genotyped patients had DC+. For IFX, DC+ was significantly correlated with the presence of FcgRIIA 131-R (p=0.033). In fact, none of the HH-genotyped patients had DC+. Further, an association between FcgRIIA-131R allele and poor response to IFX was noted (p=0.059) while all HH-genotyped patients responded to IFX. For ADL, no correlation was found with both of residual DC and response to treatment. For ADL, the presence of FcgRIIA-131 R allele might be a predictive factor of non-responsiveness to TNF-blockers. The presence of FcgRIIA-131 R allele might be associated to a higher residual DC. That might be explained by a reduced biologic clearance due to a lower binding affinity to Fc portion compared to wild allele FcgRIIA-131H. Therefore, FcgR polymorphism assessment in RA patients could be a decision-making parameter to consider, as part of the personalized medicine approach.

**Conclusion:** The results of our study confirmed in a real-life setting the efficacy of SB4 in RA patients, as demonstrated by the significant reduction of DAS28ESR values after 4 and 12 months of treatment, similarly to ETA. Nonetheless, ETA seems to be able to induce a remission status earlier than SB4.

**REFERENCES**


**Disclosure of Interests:** Ramona Lucchetti: None declared, Fulvia Ceccarini: None declared, Carlo Perricone Speakers bureau: BMS; Lilly, Celgene, Sanofi, Simona Truglia: None declared, Francesca Miranda: None declared, Manuela Di Franco: None declared, Valeria Ricciere: None declared, Rossana Scivo: None declared, Antonio Sill Scavalli: None declared, Francesco Spinnelli: None declared, Cristiana Alessandri: None declared, Guido Valesini: None declared, Roberta Priori: None declared, fabrizio conti: None declared

**DOI:** 10.1136/annrheumdis-2019-eular.8031

**AB0390**

**CORRELATION BETWEEN TNF-BLOCKERS BIOAVAILABILITY AND FCGRIIA H131R POLYMORPHISM IN TUNISIAN PATIENTS WITH RHEUMATOID ARTHRITIS**

Ines Mahmoud1, Myriam Moalla1, Imen Star2, Ola Saidane3, Aicha Ben Tekaya1, Rawdha Tekaya1, Wafa Hamdi3, Saloua Aouini2, Mohamed Montaqui4, Yousr Gorgi2, Leila Abdelmoula1.

1Hospital Charles Nicolle, Rheumatology, Tunis, Tunisia; 2Hospital Charles Nicolle, Immunology, Tunis, Tunisia; 3Institute Orthopedic Mohamed Kassab, Rheumatology, Manouba, Tunisia

**Background:** Rheumatoid arthritis (RA)'s prognosis drastically improved with the introduction of TNF-blockers. However, reasons behind therapeutic failure in some patients remain unclear. Several factors might influence pharmacokinetics of these drugs by reducing their half-life and, consequently, their effectiveness. Considering Fc-containing biologics like infliximab (IFX) and adalimumab (ADL), Fc gamma receptors (FcgRs) polymorphism would be an interesting genetic candidate to focus on.

**Objectives:** The aim of our study was to determine the influence of low affinity allele FcgRIIA-131R on ADL and IFX bioavailability.

**Methods:** We enrolled RA patients treated with IFX and ADL for over six months. Blood samples were collected for each patient immediately prior to drug administration. Quantitative measurements of the residual drug concentration (DC) was carried out by a commercial enzyme-linked immunosorbent assay (ELISA) kit (Promonitor®). Then, we identified patients with DC above therapeutic cut-off (DC+) for each biologic. EULAR criteria were considered to determine treatment outcome. FcgRIIA H131R polymorphism was genotyped using PCR-SSP.

**Results:** Twenty-nine patients were included (13 treated with ADL and 16 with IFX). We identified 31.3% and 23.1% non-responders among patients treated with IFX and ADL respectively. Patients with DC+ were more frequent in ADL group (76.9%) than IFX group (43.75%).

**Conclusion:** Our study suggested a lower retention rate in RA patients switchers from Enbrel® to biosimilar etanercept (ETN) in comparison with the historic ETN patients (1). Background registry suggested a lower retention rate in RA patients switchers from Enbrel® to biosimilar etanercept (ETN) in comparison with the historic ETN patients (1). Background.

**REFERENCES**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.8031

**AB0392**

**ASSOCIATION BETWEEN FCGRIA R131H, FCGRIIA NA1/NA2 AND FCGRIBB V159F POLYMORPHISM AND RESPONSIVENESS TO BIOLOGICS IN RHEUMATOID ARTHRITIS TUNISIAN PATIENTS**

Myriam Moalla1, Ines Mahmoud1, Imen Star2, Aicha Ben Tekaya1, Ola Saidane3, Rawdha Tekaya1, Saloua Aouini2, Kawkther Ben Abdelghani2, Ahmed Lataar3, Yousr Gorgi2, Leila Abdelmoula1.

1Hospital Charles Nicolle, Rheumatology, Tunis, Tunisia; 2Hospital Charles Nicolle, Immunology, Tunis, Tunisia; 3Institute Orthopedic Mohamed Kassab, Rheumatology, Manouba, Tunisia

**Background:** Even though biologics have been used for several years in treatment of rheumatoid arthritis (RA), little is known about factors that modify their pharmacokinetics and therefore their efficacy. Polymorphisms (SNPs) in receptors for constant region Fc of IgG (FcgR) might influence the therapeutic outcome of molecules that incorporate an Fc fragment in